Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Area of Science:

• Neuroscience
• Clinical Psychology
• Genetics

Background:

• Genetically determined Intellectual Disability (ID) is a severe, intractable condition affecting cognitive abilities.
• Understanding placebo response in ID patients is crucial for accurate clinical trial interpretation.

Purpose of the Study:

• To investigate the existence and characteristics of placebo response in genetically determined ID.
• To analyze factors influencing placebo response in this population.

Main Methods:

• Systematic review of placebo-controlled, double-blind randomized clinical trials (RCTs) for core ID symptoms.
• Meta-analysis using bias-corrected standardized mean difference (Hedge's g) and meta-regression.

Main Results:

• Significant overall placebo response observed in ID patients (g = 0.468, p = 0.002).
• Placebo response noted for both subjective and objective outcome measures.
• Higher IQ and younger age correlated with increased placebo response; no response in patients with comorbid dementia.

Conclusions:

• Patients with genetically determined ID demonstrate improvement in placebo arms of RCTs.
• Mechanisms like expectancy and "placebo-by-proxy" may contribute to these effects.
• Contextual factors are vital to consider when evaluating novel treatments for ID.